Gore Joins Americas Hernia Society Quality Collaborative (AHSQC) as Silver Sponsor

Partnership latest step in Gore’s ongoing commitment to improve quality of care for hernia patients

Gore Global Registry for Endovascular Aortic Treatment Completes Enrollment

Over 5,000 patients from 114 worldwide sites provide a unique perspective of real-world conditions

GORE® TIGRIS® Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease

Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies

Now Published in the Annals of Surgery: Long-Term Favorable Results Demonstrate GORE® BIO-A® Tissue Reinforcement Efficacy in Complex Ventral Hernia Repairs

Final study results demonstrate for the first time efficacy of long-lasting absorbable biosynthetic mesh in challenging hernia repairs; has potential to end biologics era in hernia repair

First Patient Enrolled in Gore® SCAFFOLD Clinical Study for Carotid Stenting

Pivotal Multicenter Investigational Study Begins at Medical University of South Carolina (MUSC), Evaluating Safety and Efficacy of Innovative GORE® Carotid Stent

GORE® VIABAHN® Endoprosthesis Marks 20 Years of Proven Performance

Market-leading stent-graft has evolved to address range of indications, patient needs

FDA Approves First Balloon Expandable Stent Graft for Use in the Iliac Artery

GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Provides Improved Outcomes in Real-World Peripheral Arterial Disease Cases

GORE® TIGRIS® Vascular Stent Gains Health Canada Approval for Treatment of Peripheral Artery Disease

Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies

W. L. Gore & Associates Receives Innovative Technology Designation from Vizient, Inc. for GORE® SYNECOR Biomaterial

Designation recognizes products that bring improvements to the healthcare industry

First Implant Completed in Pivotal Study of GORE® TAG® Thoracic Branch Endoprosthesis

Enrollment begins on new clinical study for the first device designed specifically for the endovascular treatment of aortic arch lesions